Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ascendis Pharma A/S    ASND

ASCENDIS PHARMA A/S

(ASND)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
159.28(c) 162.15(c) 164.52(c) 168.73(c) 168.62(c) Last
377 545 174 824 59 828 178 621 188 336 Volume
+0.50% +1.80% +1.46% +2.56% -0.07% Change
More quotes
Financials
Sales 2020 8,28 M 9,98 M 9,98 M
Net income 2020 -367 M -442 M -442 M
Net cash position 2020 871 M 1 049 M 1 049 M
P/E ratio 2020 -19,6x
Yield 2020 -
Sales 2021 56,2 M 67,7 M 67,7 M
Net income 2021 -334 M -403 M -403 M
Net cash position 2021 647 M 780 M 780 M
P/E ratio 2021 -23,0x
Yield 2021 -
Capitalization 7 550 M 9 013 M 9 095 M
EV / Sales 2020 807x
EV / Sales 2021 123x
Nbr of Employees 330
Free-Float 11,2%
More Financials
Company
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto,... 
Sector
Biotechnology & Medical Research
Calendar
12/03 | 04:45pmPräsentation
More about the company
Notations Surperformance© of Ascendis Pharma A/S
Trading Rating : Investor Rating :
More Ratings
All news about ASCENDIS PHARMA A/S
11/25ASCENDIS PHARMA A/S : Announces Participation at the Evercore ISI 3rd Annual Hea..
AQ
11/25Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual He..
GL
11/20ASCENDIS PHARMA A/S : 2020 Oncology R&D Day Presentation
PU
11/11ASCENDIS PHARMA A/S : to Host Virtual Oncology R&D Day on Friday, November 20
AQ
11/11Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20
GL
11/11ASCENDIS PHARMA A/S : Reports Third Quarter 2020 Financial Results
AQ
11/11Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results
GL
11/03ASCENDIS PHARMA A/S : Appoints Dr. Mark A. Bach as Senior Vice President of Clin..
AQ
11/03Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Cli..
GL
11/02ASCENDIS PHARMA A/S : Announces Third Quarter 2020 Financial Results and Busines..
AQ
11/02Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Busine..
GL
10/23ASCENDIS PHARMA A/S : Receives Orphan Designation for TransCon™ PTH for Tr..
AQ
10/23Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for T..
GL
10/21ASCENDIS PHARMA A/S : Announces Presentations for its Endocrinology Rare Disease..
AQ
10/21Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Diseas..
GL
More news
News in other languages on ASCENDIS PHARMA A/S
08/24ASCENDIS PHARMA A/S : Veröffentlichung des Halbjahresergebnisses
08/24ASCENDIS PHARMA A/S : publication des résultats semestriels
2019ASCENDIS PHARMA A/S : Veröffentlichung des Quartalsergebnisses
2019ASCENDIS PHARMA A/S : publication des résultats trimestriels
2019EN DIRECT DES MARCHES : Kering, Renault, L'Oréal, Casino, Cellectis, Boeing, Roc..
More news
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 161,34 €
Last Close Price 141,35 €
Spread / Highest target 27,5%
Spread / Average Target 14,1%
Spread / Lowest Target 0,45%
EPS Revisions
Managers
NameTitle
Jan Møller Mikkelsen President, CEO & Executive Director
Michael Wolff Jensen Chairman, Chief Legal Officer & Senior VP
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Kennett Sprogøe Senior Vice President, Head-Innovation & Research
James Irvin Healy Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ASCENDIS PHARMA A/S21.28%9 013
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE266.71%29 915